Trial Profile
A Double-blind, Efficacy and Safety Study of Duloxetine Hydrochloride Versus Placebo in the Treatment of Japanese Children and Adolescents With Depressive Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Duloxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company; Shionogi
- 01 Apr 2022 Results published in the Journal of Child and Adolescent Psychopharmacology
- 03 Feb 2020 Status changed from recruiting to completed.
- 30 Nov 2017 Status changed from not yet recruiting to recruiting.